CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma
CCL2 和 CCR2 作为髓母细胞瘤的转移驱动因素和治疗靶点
基本信息
- 批准号:10320941
- 负责人:
- 金额:$ 77.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AntibodiesAttenuatedBindingBiological MarkersBlocking AntibodiesBloodBlood CirculationBrainBrain NeoplasmsCCL2 geneCancer EtiologyCarcinomaCause of DeathCellsCellular biologyCerebrospinal FluidCessation of lifeChildChildhoodChildhood Malignant Brain TumorCytotoxic ChemotherapyDataDevelopmentDiagnosisDiseaseDisease ProgressionDistalExcisionFDA approvedGenesGeneticHematogenousHematogenous SpreadHomingHumanImageIndividualInflammatoryLeftLeptomeningesMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of brainMembraneMetastatic toModelingMorbidity - disease rateMusNeoplasm Circulating CellsNeoplasm MetastasisNervous system structureNeuraxisNonmetastaticOrganPatientsPatternPharmaceutical PreparationsPlayPreventionPrimary NeoplasmPublicationsRadiationRecurrenceRoleSHH geneSeedsSeriesSolidSolid NeoplasmSourceSpinal CordSubgroupSurfaceSurvival RateSurvivorsTechniquesXenograft procedurebiomarker developmentchemokinechemotherapychildhood cancer mortalitycognitive disabilitydisabilityeconomic costefficacy evaluationexperienceexperimental studyimplantationimprovedin vivoknock-downmacrophagemedulloblastomamonocyte chemoattractant protein 1 receptormouse modelneoplastic cellnovel diagnosticsnovel strategiesnovel therapeuticsoverexpressionparacrinepatient derived xenograft modelphysically handicappedpre-clinicalpreventprophylacticsocialtargeted agenttargeted treatmenttherapeutic targettherapy developmenttooltranscriptometumor
项目摘要
PROJECT SUMMARY
Brain tumors are the most common solid tumor and the leading cause of cancer-related death in children.
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Dissemination (metastasis) of MB
results in seeding the leptomeningeal membranes that cover the brain and spinal cord. The unique pattern of
dissemination leads to a relatively non-empirically supported model in which medulloblastoma was assumed to
spread through passive shedding of cells into the cerebrospinal fluid, followed by distal implantation on the
surface of the nervous system. We have now demonstrated experimentally, that medulloblastoma in fact
disseminates through the blood circulation just like every other known type of human cancer, with
hematogenously disseminated circulating tumor cells (CTCs) re-homing to the leptomeningeal compartment of
the nervous system. CTCs reseed the leptomeninges almost exclusively, only rarely seeding organs outside the
central nervous system. Hematogenous dissemination of medulloblastoma is an exciting development that offers
the chance for novel approaches to the diagnosis, prevention, and treatment of metastatic medulloblastoma.
The vast majority of medulloblastoma patients experience a `metastasis free' interval by imaging before their
metastatic recurrence, which may offer a window to prevent metastatic recurrence. In patients with established
metastatic disease, identifying the genes enabling CTCs to drive metastases could prevent or ameliorate disease
progression, offering novel diagnostic and therapeutic opportunities for medulloblastoma patients. Therefore we
will:
Aim 1). Isolate and analyze circulating tumor cells from humans and mice with MB to determine the utility of
CCL2 and CCR2 as biomarkers for the development of metastases within distinct MB subgroups.
Aim 2). Manipulate CCL2/CCR2 expression using genetic/cell biology techniques to determine the contribution
of each to MB metastasis in human xenograft and genetically modified mouse models that recapitulate distinct
MB subgroups.
Aim 3). Use established FDA approved drugs and antibodies, as well as emerging drugs and tool compounds,
to block CCL2/CCR2, individually, together, and in combination with chemotherapy and craniospinal radiation
in mouse models, to determine if we can prevent, and/or treat the dissemination of MB preclinically.
There are no drugs or therapies for medulloblastoma metastases, despite the fact that metastases are the
overwhelming cause of death, and the major source of long-term morbidity. We present a series of experiments
that clarify how brain tumors can spread hematogenously, identify markers to improve diagnosis, and develop
therapies applicable in near term to the treatment of metastatic MB in children.
项目概要
脑肿瘤是最常见的实体瘤,也是儿童癌症相关死亡的主要原因。
髓母细胞瘤(MB)是最常见的恶性儿童脑肿瘤。 MB 的播散(转移)
导致覆盖大脑和脊髓的软脑膜被播种。独特的图案
传播导致了一个相对非经验支持的模型,其中髓母细胞瘤被认为是
通过细胞被动脱落到脑脊液中传播,然后远端植入
神经系统的表面。我们现在已经通过实验证明,髓母细胞瘤实际上
就像所有其他已知类型的人类癌症一样,通过血液循环传播
血行播散的循环肿瘤细胞(CTC)重新归巢至软脑膜室
神经系统。 CTC 几乎完全在软脑膜上重新播种,很少在软脑膜之外播种器官。
中枢神经系统。髓母细胞瘤的血行播散是一项令人兴奋的发展,它提供了
寻找诊断、预防和治疗转移性髓母细胞瘤的新方法的机会。
绝大多数髓母细胞瘤患者在就诊前进行影像学检查时会经历“无转移”期。
转移复发,这可能提供预防转移复发的窗口。在已确诊的患者中
转移性疾病,识别 CTC 驱动转移的基因可以预防或改善疾病
进展,为髓母细胞瘤患者提供新的诊断和治疗机会。因此我们
将要:
目标1)。使用 MB 分离并分析人类和小鼠的循环肿瘤细胞,以确定其效用
CCL2 和 CCR2 作为不同 MB 亚组内转移发展的生物标志物。
目标2)。使用遗传/细胞生物学技术操纵 CCL2/CCR2 表达以确定贡献
人类异种移植和基因改造小鼠模型中的每种MB转移都概括了不同的
MB亚组。
目标3)。使用 FDA 批准的既定药物和抗体,以及新兴药物和工具化合物,
单独、共同或与化疗和颅脊髓放疗联合阻断 CCL2/CCR2
在小鼠模型中,以确定我们是否可以在临床前预防和/或治疗 MB 的传播。
尽管转移是髓母细胞瘤转移的主要治疗手段,但目前还没有针对髓母细胞瘤转移的药物或疗法。
压倒性的死亡原因,也是长期发病的主要来源。我们提出了一系列实验
阐明脑肿瘤如何血行扩散,识别标记物以改进诊断,并开发
近期适用于治疗儿童转移性MB的疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Livia Garzia其他文献
Livia Garzia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Livia Garzia', 18)}}的其他基金
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma
CCL2 和 CCR2 作为髓母细胞瘤的转移驱动因素和治疗靶点
- 批准号:
10543072 - 财政年份:2021
- 资助金额:
$ 77.29万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 77.29万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 77.29万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 77.29万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 77.29万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 77.29万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 77.29万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 77.29万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 77.29万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 77.29万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 77.29万 - 项目类别:
Idea to Innovation